Solid tumours encompass the broad range of non-haematological cancers, including carcinomas, sarcomas, and CNS tumours, that collectively account for the majority of cancer diagnoses and deaths globally. Tumour-agnostic biomarker-driven approvals, for TMB-high, MSI-high, NTRK, and RET fusions, have established a precision oncology paradigm that transcends organ-of-origin classification. Antibody-drug conjugates and bispecific T-cell engagers represent the leading innovation modalities.
Loading articles...
